Two studies on adoptive T-cell therapy in murine melanoma models described that BTLA- CD8+ T lymphocytes were not able to control tumor development in vivo, while their BTLA+ counterpart exhibited antitumor capacity, as well as greater survival and resistance to apoptosis [78, 79]. The gene discussed is CD8A; the disease is melanoma.